Friday, August 2, 2013

NFL cheerleader is war vet

Updated?Jul 31, 2013 4:17 PM ET

?

For one Arizona Cardinals cheerleader, hearing the national anthem and seeing the American flag before games have a special meaning.

It wasn?t easy for Megan Welter to go from Iraq veteran to NFL cheerleader, but the journey, she said, was worth it.

?Our country has given us so many freedoms,? Welter told ABC15. ?To be a part of fighting for that and maintaining that means a lot. It gives me goosebumps.?

After graduating in 2007, Welter put her dance career on hold to ?to take a job that was going to be meaningful, so I decided to join the Army."

Welter finished basic training and enrolled in Officer Training school. She ended up doing a 16-month tour in Iraq.

?My job was to make sure that...the soliders that were actually out were able to communicate,? she said.

A a third-generation soldier, Welter knew she had a "100 percent chance" of going to Iraq once she went into officer training.

"I thought it was the right thing to do," Welter told azcardinals.com in 2012. "I was deployed to Joint Base Belad which is about an hour north of Baghdad. At first, it was, it was scary you know, but?it's what I signed up to do."

At 23 years old, she was charged with maintaining the communications network for the biggest base in Iraq.

In 2011, after being inspired by NFL cheerleaders who were entertaining troops during her tour, Welter tried out for the team.

Hear her tell more of her amazing story below:

Source: http://msn.foxsports.com/nfl/story/arizona-cardinals-cheerleader-megan-welter-also-an-iraq-war-vet-073113

What Happened In Boston gold price defiance Ny Post Boston Bombing 2013 Regions Bank ny times

Thursday, August 1, 2013

Kieron Dyer retires from football after injury-hit career with spells at Newcastle United, West Ham and Ipswich

[unable to retrieve full-text content]

Source: www.telegraph.co.uk --- Wednesday, July 31, 2013
Former England midfielder confirms retirement from Football after injury-hit career, and states intentions to coach. ? ? ? ? ...

Source: http://telegraph.feedsportal.com/c/32726/f/568303/s/2f6065c1/sc/13/l/0L0Stelegraph0O0Csport0Cfootball0C10A2133330CKieron0EDyer0Eretires0Efrom0Efootball0Eafter0Einjury0Ehit0Ecareer0Ewith0Espells0Eat0ENewcastle0EUnited0EWest0EHam0Eand0EIpswich0Bhtml/st

ben affleck doctor who Preakness 2013 beyonce lottery Preakness results justin bieber

Shell Q2 earnings fall on charges, higher costs

AMSTERDAM (AP) ? Royal Dutch Shell PLC has reported a 57 percent fall in second-quarter net profits as it suffered from attacks on its operations in Nigeria and it significantly wrote down the value of its shale oil fields in North America.

In addition, Europe's largest oil company abandoned long-term targets to increase production to 3.7 million barrels a day by 2014 and 4 million per day by 2018. The company has been investing heavily in new production facilities since an accounting scandal forced it to write down its proven reserves in the early 2000s.

Production of oil and gas equivalents fell 1.3 percent from a year earlier to 3.06 million barrels per day. Chief Executive Officer Peter Voser, who is due to retire next year, insisted the company's real long-term focus had always been on increasing earnings, and it will meet long-term financial goals.

Shell repeated it plans to generate $200 billion in cash flow from 2012-2015, assuming oil stays around $100 a barrel.

"We always said production targets were kind of a proxy for financial goals," Voser said.

Net profit in the quarter was $1.74 billion, down from $4.08 billion in the same period a year ago, in part because of a $2.2 billion impairment charge on its shale oil assets in North America.

The company said it had reassessed how profitable they are likely to be.

Shell's shares fell 3.9 percent to 24.595 euros in early trading in Amsterdam.

The company's earnings on the "clean current cost of supplies" measure preferred by many analysts ? which strips out one-time charges and the impact of changes in oil price in the pipeline ? would have been 20 percent lower at $4.6 billion, Shell said.

Analysts Neill Morton and Brian Gallagher of Investec said in a note on the earnings that the company's abandoning of production targets didn't come as a surprise. "We think no-one externally, at least believed it anyway."

They repeated a Buy recommendation on shares, saying that the key lesson of weaker-than-expected results from both BP and Shell is "not to get too carried away with single, blowout quarters" such as both companies had in the first quarter of 2013.

"Despite the miss, we remain positive on Shell," they wrote. Strengths include a strong balance sheet, a good dividend yield and a cheaper valuation than most European competitors.

Shell, the largest foreign oil producer in Nigeria, has suffered several attacks on its pipelines in the country's eastern delta region in recent months. Shutdowns cost it about $250 million in the second quarter and are continuing. Shell blames the attacks on thieves, though environmental groups have criticized Shell for operating wells in a region where it cannot oversee the consequences.

Voser said the company has been selling some Nigerian assets and stakes to investors in the region in order to build local support for projects.

"I think the key there is to really solve sabotage and it has to be a multi-stakeholder approach, led by the Nigerian government," he said. "In the long term, Nigeria is an important resource and we hope that we can sort some of the short to medium-term sabotage and environmental issues out."

Voser is to be replaced by Ben van Beurden, who currently oversees the company's refining and chemicals marketing businesses.

Source: http://news.yahoo.com/shell-q2-earnings-fall-charges-higher-costs-072820347.html

Stephen Covey klimt breaking bad breaking bad food network star British Open 2012 bane

Bourreau replaces Jalabert as coach of France?s national cycling team

  • By VeloNews.com
  • Published 2 hours ago

Latest Headlines

PARIS (AFP) ? Bernard Bourreau has taken over from Laurent Jalabert as coach of France?s national cycling team, the French Cycling Federation (FFC) said Wednesday.

The 44-year-old Jalabert, the world time trial champion in 1997, resigned in April following a road accident in which he suffered a broken leg and an injured shoulder.

Bourreau, 61, had been Jalabert?s assistant since 2009.

Jalabert, who retired in 2002, was last week named in a French government commission?s report into the fight against doping as having tested positive for EPO during the 1998 Tour de France after samples were retroactively tested in 2004.

Jalabert stepped down from his role as a television and radio pundit just before July?s Tour began after he was named in a French newspaper as being on the French Senate commission?s list.

He has since neither confirmed nor denied the doping allegations against him.

FILED UNDER: News / Road TAGS: Bernard Bourreau / doping / Laurent Jalabert

Source: http://velonews.competitor.com/2013/07/news/bourreau-replaces-jalabert-as-coach-of-frances-national-cycling-team_297531

where have you been rihanna world trade center kirk cousins ovechkin bks new dark knight rises trailer khloe and lamar

Glaxo case shines light on China's medical bribery

BEIJING (AP) ? Huang Dongliang says his uncle was being ignored by his low-paid cancer specialist at a Chinese government hospital. So the family gave the doctor a "hongbao," the traditional red envelope used for gifts, with 3,000 yuan ($480).

"We could feel an obvious difference" after that, said Huang, who lives in the southeastern city of Quanzhou. "The doctor started to do more checkups, to give suggestions and advice and offered a detailed chemotherapy plan."

Such informal payments pervade China's dysfunctional health system. Low salaries and skimpy budgets drive doctors, nurses and administrators to make ends meet by accepting money from patients, drug suppliers and others. Accusations last month that GlaxoSmithKline employees bribed Chinese doctors to prescribe its drugs brought international attention to the flow of illicit money. But to China's public, the practice has long been common knowledge.

Many blame a system in which the country's hospitals nearly all are state-run but get too little money from Beijing. Most of China's 2.3 million doctors are hospital employees and are barred from adding to their income by taking on second jobs.

"Physicians are way underpaid and they need to find a way to survive," said Gordon Liu, a health care economist at Peking University's Guanghua School of Management.

The ruling Communist Party has promised higher health spending as part of efforts to spread more of China's prosperity to its poor majority. But with a population of 1.3 billion, the cost of a full-scale overhaul will be daunting for Beijing. The government faces other financial demands while economic growth is slowing.

Under the current system, the state-set price to see an oncologist or other specialist is as little as 8 yuan ($1.25) ? less than the cost of a hamburger and too little to cover a hospital's expenses.

An experienced physician might earn 6,000 yuan ($980) a month. That top level is about average for an urban Chinese worker at a time when a 100-square-meter (1,000-square-foot) apartment in Beijing can cost more than 6 million yuan ($1 million).

To fill the gap, hospitals add surcharges to drug prices and assign employees sales quotas. Doctors and other employees accept money to move patients up waiting lists for surgery or to let them see the physician they prefer. Doctors, administrators and others take kickbacks from pharmaceutical companies to use more expensive drugs or use them more often. Bribes can also distort treatment by encouraging overuse of expensive drugs or procedures.

"There are many farmers and people without medical insurance, and it's they who suffer greatly," said Liu Junhai, head of the Commercial Law Research Institute of the ruling party's Renmin University.

Huang said that after his uncle was diagnosed with lung cancer last October, he went to the bigger nearby city of Xiamen, which had a reputation for "better medical ability and attitude."

"The doctor barely said anything useful after 12 or 13 days in the hospital," he said. "Then my cousin sent 3,000 yuan to get the doctor to pay more attention to my uncle."

Complaints about medical corruption have fueled public frustration at doctors, nurses and hospitals. Distraught families that pay extra are dismayed if a patient sickens or dies. That has erupted in a spate of stabbings and other violence against hospital employees.

Last year, 39 staff members of a hospital in the southern city of Gaozhou and five salespeople for drug companies were implicated in a kickback scheme that inflated medicine costs for patients, according to the newspaper Shanghai Evening Post.

The hospital director was fired and 382 employees returned 5.8 million yuan ($950,000) in improper payments, the report said.

"For the hospital's 35 drug suppliers, no matter which is selected, in order to give the hospital an incentive to sell more drugs, they will all find ways to make contact with doctors," the hospital director, Ye Guanrui, was quoted as saying. "In a hospital with 1,000 staff members, one-third will take kickbacks."

A half-dozen physicians and hospital employees approached by The Associated Press declined to talk about medical bribery, even on condition of anonymity, due to its sensitivity.

In the GlaxoSmithKline PLC case, police say employees of the British company paid doctors, hospital administrators and officials of the government and medical groups to encourage use of its medications.

Four employees have been detained. Police say they are suspected of laundering money through travel agencies to conceal the payments and evade Glaxo's internal anti-bribery controls.

Glaxo has tried to distance itself from the scandal, saying the employees acted without its knowledge and violated its policy.

Also last month, a rival drug manufacturer, AstraZeneca PLC, said police visited its office in what the company believed was an investigation of one of its sales representatives.

Last year, New York City-based Pfizer Inc. agreed to pay the U.S. government $60 million to settle charges its salespeople made improper payments to health care workers in China and other countries.

Estimates of how much outside money doctors and others receive range from 30 percent to up to 10 times their salaries, according to Peking University's Liu. He said he and colleagues have tried to gather data but hospital employees refuse to cooperate.

Despite the scrutiny directed at foreign drug suppliers, their Chinese rivals probably are more active at spreading around such payments, said Liu.

"In general, people would say domestic companies actually practice this informal payment approach almost as a common marketing strategy," he said. "For multinationals, this is not a common marketing tool."

The financial strain of health care on families is so great that it is distorting China's economy.

Until recently, few had health insurance and families saved a big share of their income to pay for medical emergencies. That left less for consumer spending, hampering the Communist Party's efforts to nurture self-sustaining economic growth based on domestic consumption instead of exports and investment.

The latest scandal could increase pressure on Chinese leaders to speed up promised health reforms.

The ruling party is promising more health care spending as part of an expansion of social welfare aimed at spreading China's new prosperity to its poor majority. The government says state-provided health insurance has been expanded to cover 95 percent of people in China, up from less than 50 percent in 2006.

Following the accusations against GlaxoSmithKline employees, the chairman of a government health panel acknowledged the link between low spending and graft.

Beijing has imposed price caps on several hundred drugs deemed essential. But that gave hospitals that add a surcharge to medicine prices an incentive to use more of them. The Cabinet's planning agency launched an investigation in July of production costs at 60 Chinese and foreign suppliers in a possible prelude to issuing new price standards.

The government has promised to ban surcharges by hospitals to reduce incentives to overuse drugs.

Beijing also has promised to pay doctors more, but Peking University's Liu said bringing them into line with comparable professions could require doubling or tripling salaries.

Instead, some reformers are urging Beijing to adopt a U.S.- or European-style system in which doctors can work second jobs and open private clinics.

___

AP researchers Fu Ting in Shanghai and Zhao Liang contributed.

Source: http://news.yahoo.com/glaxo-case-shines-light-chinas-medical-bribery-094818478.html

Chopper Live jerry brown michael buble michael buble Jenni Rivera Alive Facebook Down bo jackson

Cost controls help Pfizer, Merck weather weak quarter

By Bill Berkrot and Ransdell Pierson

(Reuters) - Big Pharma is still relying on belt-tightening to prop up financial results.

Pfizer Inc and Merck & Co said on Tuesday their quarterly results were again hit by generic competition for once top-selling products and the toll of a strong dollar on overseas revenue. Controls on marketing and administrative expenses, and other costs, helped them report earnings slightly above Wall Street estimates.

But neither company offered investors a quick return to growth based on new products, even if the worst of the "patent cliff" for best-selling drugs that have lost marketing exclusivity is behind them.

"We are managing our costs in order for us to meet our bottom line (earnings) guidance," Chief Executive Kenneth Frazier said on a conference call with analysts.

Frazier said the company continues to have faith in the value of its animal health unit and consumer healthcare business, both of which had lower sales in the quarter.

"If we were to view these assets as being more productive outside the company, we would consider other alternatives," he said.

Pfizer earlier this year completed the spinoff of its own animal health business into a new company called Zoetis , only months after selling off its nutritional products business. It aims to return billions of dollars in proceeds to investors through stock repurchases and higher dividends. But, like Merck, it is holding on for now to its consumer healthcare unit.

Pfizer Chief Executive Ian Read said the industry's best hope is a crop of new drugs and vaccines now in clinical trials that could transform treatment for cancer, cardiovascular diseases and other ailments.

"Certainly in the second half of this decade, I foresee significant products coming to market which will be a catalyst for industrial growth," he said in an interview.

The strength of the dollar, particularly against the Japanese yen, has hurt sales of many U.S. companies with extensive international business this year.

Merck said full-year sales were likely to be about 5 to 6 percent below last year's levels, Even so, it stuck to its full-year profit outlook of $3.45 to $3.55 per share, excluding special items.

Pfizer, the largest U.S. drugmaker, said second quarter revenue fell 7 percent to $12.97 billion, with 3 percent of the decline due to an unfavorable foreign exchange rate.

But Pfizer also trimmed costs and expenses by 3 percent and reiterated its full-year earnings forecast of $2.10 to $2.20 per share.

Pfizer said income, excluding special items, fell 10 percent to $4 billion, or 56 cents a share, from $4.45 billion, or 59 cents a share, a year earlier.

Merck earned $906 million, or 30 cents per share, down from $1.79 billion, or 58 cents per share, a year earlier. Excluding special items, Merck earned 84 cents a share.

A LIFT FROM U.S. HEALTH REFORM?

"It follows along with the bigger picture in healthcare where things are OK. They're not horrible, but they're not great either," said Michael Liss, portfolio manager at American Century Investments.

Liss predicted that the next big catalyst for the industry would come when U.S. healthcare reform kicks into high gear next year, helping millions more Americans get insurance coverage for doctor's visits and medications.

"People are just waiting to get insurance and then spending will pick up," Liss predicted. "The rate of growth will improve. It's going to come from people having insurance."

But Pfizer's Read said the company does not expect the Affordable Care Act to significantly bolster its sales or earnings.

"Most of those are younger and healthy patients, so we see no near-term impact on our business," he said in an interview.

Pfizer's results were hurt by generic competition for its cholesterol fighter Lipitor, formerly the world's top selling medicine. Lipitor sales fell 55 percent $545 million, while Merck saw sales of its off-patent asthma drug Singulair plunge 80 percent to $281 million.

Pfizer shares closed down 13 cents at $29.67, while Merck fell 29 cents to $48.05 on the New York Stock Exchange.

Pfizer on Monday announced plans to internally separate its commercial operations into two units for branded products and a third for generics, leading to speculation that it was looking to split up the company.

Chief Financial Officer Frank D'Amelio told analysts on a conference call on Tuesday that Pfizer would need at least three years to consider whether to break up the company, and that the reorganization was essentially a test drive to more closely examine their respective operations.

"This is all about getting the three businesses to hum internally," he said.

(Reporting by Bill Berkrot; Editing by Michele Gershberg and Richard Chang)

Source: http://news.yahoo.com/cost-controls-help-pfizer-merck-weather-weak-quarter-201003038.html

the Who jon bon jovi jon bon jovi Kliff Kingsbury Amish Mafia Dave Grohl 121212

Nokia und Microsoft wollen rund um Windows Phone noch st?rker zusammenarbeiten

Sorry, Readability was unable to parse this page for content.

Source: http://www.facebook.com/WinFuture/posts/10152080614718222

what is autism the giver march 30 rimm pauly d project adrienne rich autism

Fairy tale: Court ruling awards $3.3 billion to Indian princesses

A court ruling last week put to rest a decades-old legal battle involving scheming servants, disinherited princesses, and a forged will.

By Jeremy Ravinsky,?Correspondent / July 29, 2013

The Faridkot estate is seen in New Delhi, India, Monday, July 29. A court in Punjab state recently ruled that the will of Sir Harinder Singh Brar of Faridkot leaving all his wealth to a trust set up by his palace officials was forged.

Shivan Sarna/AP

Enlarge

A roundup of global reports

Skip to next paragraph Jeremy Ravinsky

Correspondent

Jeremy Ravinsky is an intern at the Christian Science Monitor's international desk. Born and raised in Montreal, Canada, Jeremy has lived in Boston for a number of years, attending Tufts University where he is a political science major. Before coming to the Monitor, Jeremy interned at GlobalPost in Boston and Bturn.com in Belgrade, Serbia.

Recent posts

' + google_ads[0].line2 + '
' + google_ads[0].line3 + '

'; } else if (google_ads.length > 1) { ad_unit += ''; } } document.getElementById("ad_unit").innerHTML += ad_unit; google_adnum += google_ads.length; return; } var google_adnum = 0; google_ad_client = "pub-6743622525202572"; google_ad_output = 'js'; google_max_num_ads = '1'; google_feedback = "on"; google_ad_type = "text"; // google_adtest = "on"; google_image_size = '230x105'; google_skip = '0'; // -->

Scheming servants, disinherited princesses, forged wills ? these are standard elements of fantasy. But for the daughters of Sir Harinder Singh Brar, the last Maharajah (or king) of Faridkot, a small city in India, the elements are all part of a very real saga they have endured for more than two decades.

Last Thursday, a judge in Chandigarh, in the northwest state of Punjab, awarded Mr. Brar?s daughters the equivalent of $3.3 billion after ruling that a 31-year old last will and testament that placed his estate in the hands of his servants and lawyers was a forgery. The verdict ended the decades-long legal battle and made the sisters the 33rd richest in India, according to the Guardian.

According to the Hindu newspaper, Maharajah Brar?s servants and lawyers forged the will in 1982, while the maharajah was in the grips of depression following his only son?s death. Instead of awarding his assets to his family, the fraudulent will set up the Maharawal Khewaji?Trust to manage Mr. Brar?s estate.

The suspicion about the will arose as the Maharaja excluded his mother Mohinder Kaur and his wife Narinder Kaur while all the servants, irrespective of their designation, and lawyers were appointed trustees. Amrit had been divested of all the powers of heiress on the grounds that she had married against the wishes of the late Maharaja. Deepinder had been appointed trust chairman on paltry salary of Rs 1,200 per month while Maheepinder Kaur was given a salary of Rs 1,000 a month.

Brar had been the ruler of Faridkot until 1947, when India gained independence from Britain, reports the Times of India. After independence, he was allowed to keep his fortune and properties.

The maharajah died in 1989 and three years later his daughter Amrit Kaur filed a suit against the trust, alleging that the will had been forged. And after 21 years, a court magistrate ruled that the will was a fraud, thereby making the trust?s claim to the estate illegal.

Instead, Brar?s two daughters, Amrit Kaur and Deepinder Kaur, were awarded the remainder of the former royal?s estate, which included several properties and palaces, jewels, and even a private aerodrome, reports the Daily Telegraph. A third daughter, Maheepinder Kaur, died in 2001.

However, according to the Times of India, the Maharawal Khewaji Trust is planning on challenging the ruling to an upper court, with Ranjit Singh, the trust?s legal counsel claiming that ?The will was real and it was not forged.?

Source: http://rss.csmonitor.com/~r/csmonitor/globalnews/~3/eS7smgI2n8k/Fairy-tale-Court-ruling-awards-3.3-billion-to-Indian-princesses

ibogaine jamie moyer bone cancer hossa the cell dickclark gavin degraw